The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers

Nutrition Journal

Volumn 6, Issue , 2007, Pages

  Delage, Barbara ^a   Rullier, Anne ^b   Capdepont, Maylis ^c   Rullier, Eric ^c   Cassand, Pierrette ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HÔPITAL PELLEGRIN   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; CYCLOOXYGENASE 2; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR; CELL RECEPTOR;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CANCER TISSUE; CARCINOGENESIS; CLINICAL ARTICLE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DEREGULATION; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; MALE; MUTATION; OBESITY; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; WEIGHT CHANGE; COLORECTAL TUMOR; GENE EXPRESSION; GENETICS; LIPID METABOLISM; MIDDLE AGED; PHYSIOLOGY; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; BODY WEIGHT; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; GENE EXPRESSION; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTION; RISK FACTORS; RNA, MESSENGER;

EID: 35348866351     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/1475-2891-6-20     Document Type: Article

References (71)

1. Cancer statistics, 2004. A Jemal RC Tiwari T Murray A Ghafoor A Samuels E Ward EJ Feuer MJ Thun, CA Cancer J Clin 2004 54 1 8 29 14974761
2. A genetic model for colorectal tumorigenesis. ER Fearon B Vogelstein, Cell 1990 61 5 759 767 10.1016/0092-8674(90)90186-I 2188735
3. Lessons from hereditary colorectal cancer. KW Kinzler B Vogelstein, Cell 1996 87 2 159 170 10.1016/S0092-8674(00)81333-1 8861899
4. Effect of diet, life style, and other environmental/chemopreventive factors on colorectal cancer development, and assessment of the risks. FE Ahmed, J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2004 22 2 91 147 16291519
5. Overweight, obesity, and cancer risk. F Bianchini R Kaaks H Vainio, Lancet Oncol 2002 3 9 565 574 10.1016/S1470-2045(02)00849-5 12217794
6. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. EE Calle C Rodriguez K Walker-Thurmond MJ Thun, N Engl J Med 2003 348 17 1625 1638 10.1056/NEJMoa021423 12711737
7. Nutrition, insulin, insulin-like growth factors and cancer. E Giovannucci, Horm Metab Res 2003 35 11-12 694 704 14710348
8. Epidemic obesity and the metabolic syndrome. S Haffner H Taegtmeyer, Circulation 2003 108 13 1541 1545 10.1161/01.CIR.0000088845.17586.EC 14517149
9. Hyperinsulinemia in patients with colorectal cancer. T Suehiro T Matsumata Y Shikada K Sugimachi, Hepatogastroenterology 2005 52 61 76 78 15782998
10. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. E Osawa A Nakajima K Wada S Ishimine N Fujisawa T Kawamori N Matsuhashi T Kadowaki M Ochiai H Sekihara H Nakagama, Gastroenterology 2003 124 2 361 367 10.1053/gast.2003.50067 12557142
11. Insulin in aging and cancer: antidiabetic drug Diabenol as geroprotector and anticarcinogen. IG Popovich MA Zabezhinski PA Egormin ML Tyndyk IV Anikin AA Spasov AV Semenchenko AI Yashin VN Anisimov, Int J Biochem Cell Biol 2005 37 5 1117 1129 10.1016/j.biocel.2004.08.002 15743682
12. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. T Yoshizumi T Ohta I Ninomiya I Terada S Fushida T Fujimura G Nishimura K Shimizu S Yi K Miwa, Int J Oncol 2004 25 3 631 639 15289864
13. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. N Niho M Takahashi T Kitamura Y Shoji M Itoh T Noda T Sugimura K Wakabayashi, Cancer Res 2003 63 18 6090 6095 14522940
14. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. SA Kliewer SS Sundseth SA Jones PJ Brown GB Wisely CS Koble P Devchand W Wahli TM Willson JM Lenhard JM Lehmann, Proc Natl Acad Sci U S A 1997 94 9 4318 4323 9113987 10.1073/pnas.94.9.4318
15. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. JM Lehmann JM Lenhard BB Oliver GM Ringold SA Kliewer, J Biol Chem 1997 272 6 3406 3410 10.1074/jbc.272.6.3406 9013583
16. Peroxisome proliferator-activated receptor gamma in malignant diseases. T Wang J Xu X Yu R Yang ZC Han, Crit Rev Oncol Hematol 2006 58 1 1 14 10.1016/j.critrevonc.2005.08.011 16388966
17. Loss-of-function mutations in PPAR gamma associated with human colon cancer. P Sarraf E Mueller WM Smith HM Wright JB Kum LA Aaltonen A de la Chapelle BM Spiegelman C Eng, Mol Cell 1999 3 6 799 804 10.1016/S1097-2765(01) 80012-5 10394368
18. Peroxisome proliferator activated receptor gamma expression is reduced in the colonic mucosa of acromegalic patients. F Bogazzi F Ultimieri F Raggi A Costa M Gasperi E Cecconi F Mosca L Bartalena E Martino, J Clin Endocrinol Metab 2002 87 5 2403 2406 10.1210/jc.87.5.2403 11994396
19. Peroxisome proliferator-activated receptors: nuclear control of metabolism. B Desvergne W Wahli, Endocr Rev 1999 20 5 649 688 10.1210/er.20.5.649 10529898
20. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. TC He TA Chan B Vogelstein KW Kinzler, Cell 1999 99 3 335 345 10.1016/S0092-8674(00)81664-5 10555149
21. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. RA Gupta J Tan WF Krause MW Geraci TM Willson SK Dey RN DuBois, Proc Natl Acad Sci U S A 2000 97 24 13275 13280 11087869 10.1073/pnas.97.24.13275
22. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. HE Marin MA Peraza AN Billin TM Willson JM Ward MJ Kennett FJ Gonzalez JM Peters, Cancer Res 2006 66 8 4394 4401 10.1158/0008-5472.CAN-05-4277 16618765
23. Retinoid X receptor and its partners in the nuclear receptor family. F Rastinejad, Curr Opin Struct Biol 2001 11 1 33 38 10.1016/S0959-440X(00)00165-2 11179889
24. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. H Keller C Dreyer J Medin A Mahfoudi K Ozato W Wahli, Proc Natl Acad Sci U S A 1993 90 6 2160 2164 8384714 10.1073/pnas.90.6.2160
25. Renaissance of the biologically active vitamin A derivatives: established and novel directed therapies for cancer and chemoprevention. J Brtko J Thalhamer, Curr Pharm Des 2003 9 25 2067 2077 10.2174/1381612033454144 14529416
26. 1,25-Dihydroxyvitamin D3 and retinoid X receptor expression in human colorectal neoplasms. KF Kane MJ Langman GR Williams, Gut 1995 36 2 255 258 7883226 10.1136/gut.36.2.255
27. Retinoids differentially regulate the proliferation of colon cancer cell lines. LV Stewart ML Thomas, Exp Cell Res 1997 233 2 321 329 10.1006/excr.1997.3569 9194494
28. Retinoids and their receptors in cancer development and chemoprevention. SY Sun R Lotan, Crit Rev Oncol Hematol 2002 41 1 41 55 10.1016/S1040-8428(01) 00144-5 11796231
29. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. W Kutchera DA Jones N Matsunami J Groden TM McIntyre GA Zimmerman RL White SM Prescott, Proc Natl Acad Sci U S A 1996 93 10 4816 4820 8643486 10.1073/pnas.93.10.4816
30. Expression of cyclooxygenase-2 in human lung carcinoma. H Wolff K Saukkonen S Anttila A Karjalainen H Vainio A Ristimaki, Cancer Res 1998 58 22 4997 5001 9823297
31. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. WL Yang H Frucht, Carcinogenesis 2001 22 9 1379 1383 10.1093/carcin/22.9.1379 11532858
32. Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. S Adachi M Okuno R Matsushima-Nishiwaki Y Takano S Kojima SL Friedman H Moriwaki Y Okano, Hepatology 2002 35 2 332 340 10.1053/jhep.2002.31164 11826406
33. The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid. AL Eisinger LD Nadauld DN Shelton PW Peterson RA Phelps S Chidester DM Stafforini SM Prescott DA Jones, J Biol Chem 2006 281 29 20474 20482 10.1074/jbc.M602859200 16699180
34. A high-fat diet generates alterations in nuclear receptor expression: prevention by vitamin A and links with cyclooxygenase-2 and beta-catenin. B Delage C Bairras B Buaud V Pallet P Cassand, Int J Cancer 2005 116 6 839 846 10.1002/ijc.21108 15856452
35. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. TH Chang E Szabo, Cancer Res 2000 60 4 1129 1138 10706135
36. PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. T Takashima Y Fujiwara K Higuchi T Arakawa Y Yano T Hasuma S Otani, Int J Oncol 2001 19 3 465 471 11494023
37. Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. JA Brockman RA Gupta RN Dubois, Gastroenterology 1998 115 5 1049 1055 10.1016/S0016-5085(98)70072-1 9797355
38. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. YC Yang YP Tsao TC Ho IP Choung, Int J Gynecol Cancer 2007 17 2 418 425 10.1111/j.1525-1438.2006. 00866.x 17316361
39. Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. GY Zhang N Ahmed C Riley K Oliva G Barker MA Quinn GE Rice, Br J Cancer 2005 92 1 113 119 10.1038/sj.bjc.6602244 15583697
40. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. G Kristiansen J Jacob AC Buckendahl R Grutzmann I Alldinger B Sipos G Kloppel M Bahra JM Langrehr P Neuhaus M Dietel C Pilarsky, Clin Cancer Res 2006 12 21 6444 6451 10.1158/1078-0432.CCR-06-0834 17085658
41. Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARgamma-coactivator 1 (PGC-1). J Feilchenfeldt MA Brundler C Soravia M Totsch CA Meier, Cancer Lett 2004 203 1 25 33 10.1016/j.canlet.2003.08.024 14670614
42. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. RN DuBois R Gupta J Brockman BS Reddy SL Krakow MA Lazar, Carcinogenesis 1998 19 1 49 53 10.1093/carcin/19.1.49 9472692
43. APC-dependent suppression of colon carcinogenesis by PPARgamma. GD Girnun WM Smith S Drori P Sarraf E Mueller C Eng P Nambiar DW Rosenberg RT Bronson W Edelmann R Kucherlapati FJ Gonzalez BM Spiegelman, Proc Natl Acad Sci U S A 2002 99 21 13771 13776 12370429 10.1073/pnas.162480299
44. The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. EA Jansson A Are G Greicius IC Kuo D Kelly V Arulampalam S Pettersson, Proc Natl Acad Sci U S A 2005 102 5 1460 1465 15665104 10.1073/pnas.0405928102
45. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. AM Lefebvre I Chen P Desreumaux J Najib JC Fruchart K Geboes M Briggs R Heyman J Auwerx, Nat Med 1998 4 9 1053 1057 10.1038/2036 9734399
46. Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues. S Nomura A Nakajima S Ishimine N Matsuhashi T Kadowaki M Kaminishi, J Exp Clin Cancer Res 2006 25 3 443 448 17167986
47. Acetylation of nuclear receptors in cellular growth and apoptosis. M Fu C Wang X Zhang RG Pestell, Biochem Pharmacol 2004 68 6 1199 1208 10.1016/j.bcp.2004.05.037 15313417
48. The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Y Shi M Hon RM Evans, Proc Natl Acad Sci U S A 2002 99 5 2613 2618 11867749 10.1073/pnas.052707099
49. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Y Barak D Liao W He ES Ong MC Nelson JM Olefsky R Boland RM Evans, Proc Natl Acad Sci U S A 2002 99 1 303 308 11756685 10.1073/pnas.012610299
50. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. BH Park B Vogelstein KW Kinzler, Proc Natl Acad Sci U S A 2001 98 5 2598 2603 11226285 10.1073/pnas.051630998
51. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. R Mukherjee PJ Davies DL Crombie ED Bischoff RM Cesario L Jow LG Hamann MF Boehm CE Mondon AM Nadzan JR Paterniti Jr. RA Heyman, Nature 1997 386 6623 407 410 10.1038/386407a0 9121558
52. Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice. Q Shen GW Cline GI Shulman MD Leibowitz PJ Davies, J Biol Chem 2004 279 19 19721 19731 10.1074/jbc.M311729200 14998989
53. Differential expression of retinoic acid receptors in normal and malignant esophageal tissues. A Kumar J Kaur TK Chattopadhyay M Mathur R Ralhan, J Exp Ther Oncol 2004 4 1 1 8 15255287
54. Analysis of vitamin D-receptor (VDR) and retinoid X-receptor alpha in breast cancer. M Friedrich R Axt-Fliedner C Villena-Heinsen W Tilgen W Schmidt J Reichrath, Histochem J 2002 34 1-2 35 40 10.1023/A:1021343825552 12365798
55. Altered localization of retinoid X receptor alpha coincides with loss of retinoid responsiveness in human breast cancer MDA-MB-231 cells. T Tanaka BL Dancheck LC Trifiletti RE Birnkrant BJ Taylor SH Garfield U Thorgeirsson LM De Luca, Mol Cell Biol 2004 24 9 3972 3982 15082790 10.1128/MCB.24.9.3972-3982.2004
56. Unliganded RXR acts as an inhibitory factor on troglitazone-induced activation. T Monden M Yamada Y Nihei M Kishi T Tomaru S Ishii T Hashida N Shibusawa K Hashimoto T Satoh K Kasai M Mori, Life Sci 2004 76 7 731 741 10.1016/j.lfs.2004.04.061 15581905
57. Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells. SY James F Lin SK Kolluri MI Dawson XK Zhang, Cancer Res 2003 63 13 3531 3538 12839938
58. Methylation of conserved CpG sites neighboring the beta retinoic acid response element may mediate retinoic acid receptor beta gene silencing in MCF-7 breast cancer cells. A Arapshian YS Kuppumbatti R Mira-y-Lopez, Oncogene 2000 19 35 4066 4070 10.1038/sj.onc.1203734 10962564
59. Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. S Cote D Sinnett RL Momparler, Anticancer Drugs 1998 9 9 743 750 10.1097/00001813-199810000-00001 9840718
60. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. AK Virmani A Rathi S Zochbauer-Muller N Sacchi Y Fukuyama D Bryant A Maitra S Heda KM Fong F Thunnissen JD Minna AF Gazdar, J Natl Cancer Inst 2000 92 16 1303 1307 10.1093/jnci/92.16.1303 10944551
61. Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines. L Emionite F Galmozzi M Grattarola F Boccardo L Vergani S Toma, Anticancer Res 2004 24 6 4019 4024 15736447
62. Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. MO Lee SY Han S Jiang JH Park SJ Kim, Biochem Pharmacol 2000 59 5 485 496 10.1016/S0006-2952(99)00355-X 10660115
63. Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma. K Sano T Takayama K Murakami I Saiki M Makuuchi, Clin Cancer Res 2003 9 10 Pt 1 3679 3683 14506158
64. Immunohistochemical analysis of retinoic acid receptor-alpha in human breast tumors: retinoic acid receptor-alpha expression correlates with proliferative activity. BM van der Leede J Geertzema TM Vroom D Decimo Y Lutz PT van der Saag B van der Burg, Am J Pathol 1996 148 6 1905 1914 8669476
65. Overweight, obesity, and colorectal cancer screening: disparity between men and women. M Heo DB Allison KR Fontaine, BMC Public Health 2004 4 1 53 15533259 10.1186/1471-2458-4-53
66. Body mass index and risk of colorectal cancer in women (United States). J Lin SM Zhang NR Cook KM Rexrode IM Lee JE Buring, Cancer Causes Control 2004 15 6 581 589 10.1023/B:CACO.0000036168.23351.f1 15280637
67. Vitamin A homeostasis and diabetes mellitus. TK Basu C Basualdo, Nutrition 1997 13 9 804 806 10.1016/S0899-9007(97)00192-5 9290094
68. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. OC Trifan T Hla, J Cell Mol Med 2003 7 3 207 222 10.1111/j.1582-4934.2003.tb00222. x 14594546
69. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. H Sano Y Kawahito RL Wilder A Hashiramoto S Mukai K Asai S Kimura H Kato M Kondo T Hla, Cancer Res 1995 55 17 3785 3789 7641194
70. Alteration of gene expression in macroscopically normal colonic mucosa from individuals with a family history of sporadic colon cancer. CY Hao DH Moore P Wong JL Bennington NM Lee LC Chen, Clin Cancer Res 2005 11 4 1400 1407 10.1158/1078-0432.CCR-04-1942 15746039
71. PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. B Glinghammar J Skogsberg A Hamsten E Ehrenborg, Biochem Biophys Res Commun 2003 308 2 361 368 10.1016/S0006-291X(03) 01384-6 12901877